Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

COVID-19 Hit New Medication Starts Across Broad Therapeutic Areas

Executive Summary

Categories from asthma to high blood pressure to cancer showed reductions in new medication users in 2020, likely caused by fewer new diagnoses because of the pandemic, a report from Cigna’s Evernorth shows.

You may also be interested in...



Specialty Drugs Outweighed Traditional Drug Spending For The First Time

Drugs for inflammatory conditions and cancer drove the increase in spending among the pharmacy benefit manager’s commercial plans, according to a drug trend report from Cigna's Evernorth.

Cigna Switch Program Intensifies Competitive Dynamics For Cosentyx

A new pilot program by the insurer is offering a $500 debit card to patients who switch from the blockbuster Novartis psoriasis drug to Lilly's rival Taltz or other preferred drugs.

J&J's Next Immunology Act Centers On Nipocalimab For Autoantibody-Driven Diseases

The company has ramped up a broad R&D program for the FcRn inhibitor in 11 autoantibody-driven disease areas.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel